{"id":"NCT01920711","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-18","primaryCompletion":"2019-06-07","completion":"2019-06-07","firstPosted":"2013-08-12","resultsPosted":"2020-09-29","lastUpdate":"2020-09-29"},"enrollment":4822,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]},{"type":"DRUG","name":"Valsartan","otherNames":[]}],"arms":[{"label":"LCZ696","type":"EXPERIMENTAL"},{"label":"Valsartan","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.","primaryOutcome":{"measure":"Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.","timeFrame":"Total follow up time (up to 57 months)","effectByArm":[{"arm":"LCZ696","deltaMin":894,"sd":null},{"arm":"Valsartan","deltaMin":1009,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0587"},{"comp":"OG000 vs OG001","p":"0.0556"},{"comp":"OG000 vs OG001","p":"0.6241"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":715,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Colombia","Croatia","Czechia","Denmark","Finland","France","Germany","Greece","Guatemala","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Norway","Peru","Philippines","Poland","Romania","Russia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40839760","40488583","40265602","40088233","39873282","39570234","39439294","39387766","39217577","39212045","39210725","39193709","38932589","38904251","38842957","38841854","38537919","38390793","38104937","37366061","37350280","37225045","36647690","36632831","36050227","35895867","35717169","35603667","35603665","35483796","34918855","34807713","34796742","34392331","34097449","33998278","33888245","33866828","33839075","33727901","33714741","33189633","32845715","32731928","32241619","32192799","31806129","31736342","31736337","31726194","31475794","31302043","29980595","29890892","28662936","25415957"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1424,"n":2419},"commonTop":["Hypotension","Renal impairment","Hypertension","Hyperkalaemia","Urinary tract infection"]}}